Advanced solid tumor Trials in Shijiazhuang, China
Conditions / Advanced solid tumor / Shijiazhuang, China
Advanced solid tumor has been the subject of sustained clinical investigation across multiple research sites.
10 total trials for this combination
Trials
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT05170958 | A Phase I/II Clinical Study of LBL-024 in Patients With Advanced Malignant Tumors | RECRUITING | PHASE1/PHASE2 |
| NCT05372120 | A Clinical Trial of ICP-192 in Treated Patients With Advanced Solid Tumors With FGF/FGFR Gene Alterations | UNKNOWN | PHASE2 |
| NCT06625593 | A First-in-Human (FIH) Study of BG-C137, an Anti-Fibroblast Growth Factor Receptor 2b (FGFR2b) Antibody Drug Conjugate, in Participants With Advanced Solid Tumors | RECRUITING | — |
| NCT03704246 | Recombinant Human Anti-PD-1 Monoclonal Antibody HX008 Injection for the Treatment of Advanced Solid Tumors | UNKNOWN | PHASE2 |
| NCT06223256 | A Study of NBL-028 in Patients With Advanced Solid Tumors | RECRUITING | PHASE1 |
| NCT05508100 | Dose Confirmation and Dose Expansion Phase 1 Study of IO-108 and IO-108 + Anti-PD-1 in Solid Tumors | COMPLETED | PHASE1 |
| NCT05279300 | A Study of CS5001 in Patients With Advanced Solid Tumors and Lymphomas | RECRUITING | PHASE1 |
| NCT04282278 | Study of Anti-PD-1 Antibody Multimodal Combination as First-line Treatment on Time Window of Advanced Solid Tumor | UNKNOWN | PHASE2 |
| NCT04237805 | A Phase I/II Clinical Study of SAF-189s in Non-small Cell Lung Cancer (NSCLC) Patients | RECRUITING | PHASE1/PHASE2 |
| NCT04805307 | Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy, Phase 1 Study of CMG901 | COMPLETED | PHASE1 |